Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Bevacizumab, Dacarbazine and Interferon Alfa-2a Combination as a First-Line Therapy in Patients With Locally Advancing or Metastatic Melanoma

NCT00308607 is registered in ClinicalTrials.gov with University of Turku as lead sponsor.

NCT NCT00308607
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00308607 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Bevacizumab, Dacarbazine and Interferon Alfa-2a Combination as a First-Line Therapy in Patients With Locally Advancing or Metastatic Melanoma
Lead sponsor
University of Turku
Phase
Phase 2
Overall status
Completed
Start date
August 31, 2005
Completion date
April 30, 2009
Enrollment
27 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic melanoma